Compare Main Street Capital Corporation (MAIN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Novo Nordisk A/S — how do they compare? Main Street Capital Corporation trades at $53.74 (market cap $5.09B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 32.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.84%). Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 89 Days and Novo Nordisk A/S for 116 Days on average.
| MAIN | NVO | |
|---|---|---|
Market Cap | $5.09B | $165.31B |
Volume | 524,060 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $64.60 | $63.98 |
52-Week Low | $49.63 | $35.29 |
Typical Hold Time | 89 Days | 116 Days |
Enterprise Value | $7.54B | $179.56B |
Dividend Yield | 5.84% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $53.74, down 0.81% on the day, with a bearish technical signal from moving averages. The stock shows strong profitability with an 80.77% net income margin and a P/E of 10.94, indicating potential undervaluation. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. The company maintains a consistent monthly dividend, recently paying $0.27 per share, supporting income-focused investors.
The outlook is cautiously optimistic given MAIN's robust fundamentals and analyst consensus price target of $58.33, suggesting upside. However, risks include softening revenue projections for 2026 and bearish technical trends. Investors should weigh the high dividend yield against potential earnings volatility and market sentiment shifts.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
